Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Liver Diseases

Free Subscription 26.01.2026 1 AJR Am J Roentgenol 1 Am J Gastroenterol 1 Am J Pathol 3 BMC Cancer 6 BMC Gastroenterol 1 Br J Surg 1 Cancer Res 4 Clin Res Hepatol Gastroenterol 1 Dig Dis Sci 4 Endoscopy 1 Eur Radiol 1 Gastroenterology 1 Gastrointest Endosc 2 Gut 3 Hepatology 1 Indian J Gastroenterol 7 J Hepatol 1 Minerva Gastroenterol (Torino) 2 PLoS One 2 Radiol Imaging Cancer 1 Radiology 1 Transplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. CHOI SJ, Kim DH, Choi SH, Shin YM, et al
   Enhancing Capsule on Dynamic Liver CT: Association With Hepatocellular Carcinoma Diagnosis Using LI-RADS Version 2018.
   AJR Am J Roentgenol. 2026 Jan 21. doi: 10.2214/AJR.25.34197.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

2. JARRAH M, Rich NE, Figueroa G, Garces SM, et al
   Treatment Delays and Survival in Patients with Hepatocellular Carcinoma: A Multicenter Cohort Study.
   Am J Gastroenterol. 2026 Jan 21. doi: 10.14309/ajg.0000000000003923.
   PubMed         Abstract available
   
   

   
   Am J Pathol

3. HRNCIR HR, Goodloe B, Bombin S, Sun SJ, et al
   Quantitative 3D Imaging of Mouse and Human Intrahepatic Bile Ducts in Homeostasis and Liver Injury.
   Am J Pathol. 2026;196:445-459.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. YANG X, Wu Y, Zhang Q, Zhou Y, et al
   Multi-cohort analysis and experimental study on the function of squalene epoxidase as a ferroptosis inhibitor in HCC.
   BMC Cancer. 2025;26:81.
   PubMed         Abstract available
   
   
5. HUANG Z, Zhu T, Chen X, Piao M, et al
   Postoperative adjuvant TACE combined with lenvatinib and immune checkpoint inhibitors for hepatocellular carcinoma with high recurrence risks: a multicenter retrospective study.
   BMC Cancer. 2026 Jan 20. doi: 10.1186/s12885-026-15586.
   PubMed        
   
   
6. ZHOU J, Dong C, Xu S, Wang J, et al
   ppAT drives glutamine-dependent purine biosynthesis and malignant progression in hepatocellular carcinoma.
   BMC Cancer. 2026 Jan 21. doi: 10.1186/s12885-025-15512.
   PubMed        
   
   

   
   BMC Gastroenterol

7. LIANG H, Lin T, Hu Y, Sun X, et al
   MiR-199b-5p inhibition improves inflammation and oxidative stress damage in OA-induced non-alcoholic fatty liver disease through targeting SIRT1.
   BMC Gastroenterol. 2025;26:50.
   PubMed         Abstract available
   
   
8. ELGAMAL H, Elhammady D, El-Khair SMA, El-Badrawy A, et al
   Melanoma antigen genes A1 and A3 as predictors of treatment response and survival in HCV-associated hepatocellular carcinoma: a prospective study.
   BMC Gastroenterol. 2026 Jan 22. doi: 10.1186/s12876-025-04574.
   PubMed         Abstract available
   
   
9. FAN M, Yang Z, Xu Z, Cong Z, et al
   Outcomes of bile duct-guided right hepatic inflow occlusion and extended procedures in laparoscopic liver surgery.
   BMC Gastroenterol. 2026 Jan 21. doi: 10.1186/s12876-026-04622.
   PubMed        
   
   
10. XU X, Li J, Yu H, Huang J, et al
    Interpretable model for early prediction of 28-day mortality in patients with cirrhosis and sepsis: a multi-cohort ICU study.
    BMC Gastroenterol. 2026 Jan 20. doi: 10.1186/s12876-026-04620.
    PubMed        
    
    
11. CHEN G, Wang M, Huang X, Zhang Z, et al
    Tumor growth rate for prognostic stratification and treatment optimization in unresectable hepatocellular carcinoma treated with TACE combined with systemic therapy.
    BMC Gastroenterol. 2026 Jan 19. doi: 10.1186/s12876-025-04596.
    PubMed         Abstract available
    
    
12. ARAKI T, Yokoyama K, Ida K, Inagaki Y, et al
    Endoplasmic reticulum stress enhances unsaturated fatty acid-induced hepatocyte injury in human pluripotent stem cell-derived hepatic culture.
    BMC Gastroenterol. 2026 Jan 17. doi: 10.1186/s12876-026-04616.
    PubMed        
    
    

    
    Br J Surg

13. MCCLEMENTS J, Koh A, Lucocq J, Sellappan H, et al
    Adherence to Best Practice Guidelines for the Management of Intrahepatic Cholangiocarcinoma: Results from the Capbil Study.
    Br J Surg. 2026 Jan 23:znag001. doi: 10.1093.
    PubMed        
    
    

    
    Cancer Res

14. LIU Q, Liu Y, Zhou Y, Liang L, et al
    Intratumoral Lactobacillus johnsonii Enhances Sensitivity to PD-1 Blockade by Inducing CD8+ T Cell Expansion in Hepatocellular Carcinoma.
    Cancer Res. 2026 Jan 22. doi: 10.1158/0008-5472.CAN-25-0346.
    PubMed         Abstract available
    
    

    
    Clin Res Hepatol Gastroenterol

15. MARTINEZ-SANCHEZ FD, Agurre-Villarreal D, Argaiz ER, Rosales-Renteria LA, et al
    Physiology-Guided Albumin Therapy in Decompensated Cirrhosis: The Expanding Role of Point-of-Care Ultrasound.
    Clin Res Hepatol Gastroenterol. 2025 Dec 9:102744.
    PubMed         Abstract available
    
    
16. LEPOUR M, Delorme A, Goffaux A, Trefois P, et al
    Low muscle density and Five Times Sit-to-Stand Test predict poor outcome in liver transplant candidates.
    Clin Res Hepatol Gastroenterol. 2025 Dec 10:102743.
    PubMed         Abstract available
    
    
17. WANG Z, Wu L, Bai K, Qiu M, et al
    Evaluating the accuracy of the histological diagnosis in unexplained liver injury: A retrospective study.
    Clin Res Hepatol Gastroenterol. 2026;50:102747.
    PubMed         Abstract available
    
    
18. ALSALEH T, Harb A, Chapagain P, Dakkak B, et al
    Prevalence and risk factors of portopulmonary hypertension in chronic liver disease: systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2026;50:102748.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

19. TSUJI Y, Namisaki T, Yoshjji H
    Response to the Letter to the Editor Regarding "Risk Factors for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Hepatocellular Carcinoma".
    Dig Dis Sci. 2026 Jan 23. doi: 10.1007/s10620-025-09642.
    PubMed        
    
    

    
    Endoscopy

20. SUZUKI Y, Miwa H, Endo K, Oishi R, et al
    Laser ablation for tumor ingrowth of the bridging stent via the endoscopic ultrasound-guided hepaticogastrostomy.
    Endoscopy. 2026;58.
    PubMed        
    
    
21. SOGA K, Yamaguchi M, Kuwada M, Shirahashi R, et al
    Direct-view endoscopic ultrasound-guided fibrotic hepaticojejunostomy stricture managed with a modified stent tube.
    Endoscopy. 2026;58.
    PubMed        
    
    
22. MIWA H, Tsuchiya H, Tsunoda S, Endo K, et al
    Simultaneous bridging and antegrade stent-in-stent placement via endoscopic ultrasound-guided hepaticogastrostomy using novel multi-hole metal stents.
    Endoscopy. 2026;58.
    PubMed        
    
    
23. HARA H, Ishii H, Katsumata R, Ashikawa T, et al
    Rescue endoscopic ultrasound-guided hepaticogastrostomy with antegrade stenting for food-impacted complete papillary occlusion via intentional stent-mesh traversal.
    Endoscopy. 2026;58.
    PubMed        
    
    

    
    Eur Radiol

24. ZHAO D, Liu J, Wan J, Yang L, et al
    Clinical outcomes after TIPS: comparison of patients with a history of partial splenic embolization vs splenectomy in cirrhosis.
    Eur Radiol. 2026 Jan 21. doi: 10.1007/s00330-025-12268.
    PubMed         Abstract available
    
    

    
    Gastroenterology

25. HIRODE G, Zangneh HF, Cerocchi O, Khalili K, et al
    Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial.
    Gastroenterology. 2026 Jan 20:S0016-5085(25)05993.
    PubMed         Abstract available
    
    

    
    Gastrointest Endosc

26. WANG Z, Li H, Zeng Z, Zhang W, et al
    Endoscopic Ultrasound-Guided Coils Embolization with Cyanoacrylate Injection versus Transjugular Intrahepatic Portosystemic Shunt with Variceal Embolization for Gastric Variceal Bleeding: A Multicenter Propensity-Matched Analysis.
    Gastrointest Endosc. 2026 Jan 21:S0016-5107(26)00043.
    PubMed         Abstract available
    
    

    
    Gut

27. CHANG YP, Chen YC, Cheng PN, Fang YJ, et al
    Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease.
    Gut. 2026 Jan 20:gutjnl-2025-337275. doi: 10.1136/gutjnl-2025-337275.
    PubMed         Abstract available
    
    
28. XI Y, Liu L, Kim JW, Zhang M, et al
    Targeting ADAR1-mediated RNA editing inhibits hepatic stellate cell activation and liver fibrosis by enhancing HSC-intrinsic innate immunity.
    Gut. 2026 Jan 19:gutjnl-2025-335942. doi: 10.1136/gutjnl-2025-335942.
    PubMed         Abstract available
    
    

    
    Hepatology

29. NG WH, Yeo YH, Kim H, Seki E, et al
    Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data.
    Hepatology. 2026;83:333-343.
    PubMed         Abstract available
    
    
30. ZHANG P, Liu D, Wu L, Wu X, et al
    Neutrophil serine proteases NE and PR3 controlled by the miR-223/STAT3 axis potentiate MASH and liver fibrosis.
    Hepatology. 2026;83:317-332.
    PubMed         Abstract available
    
    
31. CIRIACI N, Bertin L, Rautou PE
    Genetic predisposition to porto-sinusoidal vascular disorder.
    Hepatology. 2026;83:409-424.
    PubMed         Abstract available
    
    

    
    Indian J Gastroenterol

32. JOTHIMANI D, Simon E, P M ASR, Ramachandran H, et al
    Serum melatonin predicts hepatic encephalopathy in patients with liver cirrhosis.
    Indian J Gastroenterol. 2026 Jan 20. doi: 10.1007/s12664-025-01922.
    PubMed         Abstract available
    
    

    
    J Hepatol

33. WOLF C, Lange K, Stallmach A, Tannapfel A, et al
    A rare vascular puzzle: Portal hypertension and hepatic lesions.
    J Hepatol. 2026;84:e59-e61.
    PubMed        
    
    
34. ZHOU XD, Lian LY, Chen QF, Kim SU, et al
    Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD.
    J Hepatol. 2026;84:254-265.
    PubMed         Abstract available
    
    
35. MOLZEN L, Winther-Jensen M, Madsen LG, Osler M, et al
    Risk of alcohol-related liver disease and cause-specific mortality in individuals seeking treatment for alcohol use disorder.
    J Hepatol. 2026;84:266-274.
    PubMed         Abstract available
    
    
36. YAMAGUCHI H, Yoneyama Y, Ichimura K, Ohtsu K, et al
    Reversal of ACLF and ALF using whole blood extracorporeal system combining HLA-depleted liver organoids with granulocyte-monocyte apheresis.
    J Hepatol. 2026;84:293-307.
    PubMed         Abstract available
    
    
37. WONG YJ, Lam L, Soret PA, Lemoinne S, et al
    Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.
    J Hepatol. 2025 Oct 3:S0168-8278(25)02519-X. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
38. YOUNOSSI ZM, Stepanova M, Schattenberg JM, Henry L, et al
    Measuring health-related quality of life and patient-reported outcomes in chronic liver disease.
    J Hepatol. 2026;84:457-472.
    PubMed         Abstract available
    
    
39. 
    EASL Clinical Practice Guidelines on vascular diseases of the liver.
    J Hepatol. 2026;84:399-456.
    PubMed         Abstract available
    
    

    
    Minerva Gastroenterol (Torino)

40. GALLETTI G, Formisano E, Ghezzi A, Tozzi M, et al
    Non-invasive staging of hepatic steatosis by Quantification Attenuation Index (QAI).
    Minerva Gastroenterol (Torino). 2026 Jan 22. doi: 10.23736/S2724-5985.25.03829.
    PubMed         Abstract available
    
    

    
    PLoS One

41. SU T, Lai S, Chen H
    Intestinal decontamination with rifaximin attenuates LSEC dysfunction and liver fibrosis in mice.
    PLoS One. 2026;21:e0340664.
    PubMed         Abstract available
    
    
42. NISHIMURA T, Kirihara A, Egusa M, Nishiyama N, et al
    Development of a novel scoring system to determine the optimal timing of esophagogastroduodenoscopy following portosystemic shunt occlusion.
    PLoS One. 2026;21:e0341330.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

43. YU C, Wang X, Tang S, Li Y, et al
    Gadoxetic Acid-enhanced MRI Radiomics Features of Tumor Margins for Predicting High-Risk Solitary Hepatocellular Carcinoma Aggressiveness and Prognosis.
    Radiol Imaging Cancer. 2026;8:e250220.
    PubMed         Abstract available
    
    
44. WEI R, Zuo M, Li W, Liu W, et al
    Risk Model for Predicting Aggressive Recurrence of Hepatocellular Carcinoma after Microwave Ablation Using MRI and Clinical Parameters.
    Radiol Imaging Cancer. 2026;8:e250304.
    PubMed         Abstract available
    
    

    
    Radiology

45. CHENG MQ, Hu HT, Wu SH, Huang H, et al
    Prospective Multicenter Evaluation of Hepatocellular Carcinoma Surveillance under American Association for the Study of Liver Diseases Version 2023 Guidance.
    Radiology. 2026;318:e252252.
    PubMed         Abstract available
    
    

    
    Transplantation

46. FALEIRO MD, de M Ogawa T, Correia PP, Perim V, et al
    Updated Systematic Review and Meta-Analysis of Duct-to-duct Versus Hepaticojejunostomy Reconstruction After Liver Transplantation for Primary Sclerosing Cholangitis.
    Transplantation. 2026 Jan 23. doi: 10.1097/TP.0000000000005639.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum